We are live on ! Find out more
SB

Samsara BioCapital Portfolio holdings

AUM $1.22B
1-Year Est. Return 242.83%
This Fund
S&P 500
This Quarter Est. Return
+27.21%
1 Year Est. Return
+242.83%
3 Year Est. Return
+1,579.88%
5 Year Est. Return
+1,852.28%
10 Year Est. Return
–
AUM
$994M
AUM Growth
+$636M
Cap. Flow
+$7.47M
Cap. Flow %
0.75%
Top 10 Hldgs %
86.65%
Holding
46
New
10
Increased
4
Reduced
16
Closed
3

Top Buys

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$47.8M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$7.13M
3
KRON
Kronos Bio
KRON
+$5.22M
4
BLSA
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
+$3.22M
5
CHFW.U
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
+$3.06M

Top Sells

Rank Stock Value
1
CVAC
CureVac
CVAC
+$21.1M
2
COGT icon
Cogent Biosciences
COGT
+$9.14M
3
SWTX
SpringWorks Therapeutics
SWTX
+$8.72M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$6.39M
5
ALLK
Allakos
ALLK
+$4.8M

Sector Composition

Rank Sector Weight
1 Financials 51.32%
2 Healthcare 47.85%
3 Miscellaneous 0.83%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JYAC
1
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$507M 50.99%
+5,223
New +$53.2K
NKTX icon
2
Nkarta
NKTX
$206M
$125M 12.58%
2,034,703
– –
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$50.3M 5.05%
+3,168,388
New +$47.8M
FMTX
4
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$49.5M 4.98%
1,418,529
-73,634
-5% -$3.21M
STRO icon
5
Sutro Biopharma
STRO
$259M
$36.4M 3.66%
167,558
– –
SYRS
6
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$21.8M 2.2%
218,920
+78,125
+55% +$7.13M
ALLK
7
DELISTED
Allakos
ALLK
$20.5M 2.06%
146,259
-46,075
-24% -$4.8M
SWTX
8
DELISTED
SpringWorks Therapeutics
SWTX
$19M 1.91%
262,572
-135,445
-34% -$8.72M
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$16.4M 1.65%
2,372,476
-998,002
-30% -$6.39M
ODT
10
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$15.7M 1.57%
815,421
– –
ICPT
11
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$9.97M 1%
403,688
– –
ACRS icon
12
Aclaris Therapeutics
ACRS
$783M
$8.82M 0.89%
1,362,612
-790,653
-37% -$3.34M
VRNA
13
DELISTED
Verona Pharma
VRNA
$7.78M 0.78%
1,111,112
– –
CVAC
14
DELISTED
CureVac
CVAC
$7.73M 0.78%
95,318
-275,067
-74% -$21.1M
BCEL
15
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$7.67M 0.77%
474,943
-142,617
-23% -$2.14M
SYRE icon
16
Spyre Therapeutics
SYRE
$8.04B
$6.96M 0.7%
35,349
– –
COGT icon
17
Cogent Biosciences
COGT
$5.65B
$6.61M 0.67%
588,961
-831,494
-59% -$9.14M
RYTM icon
18
Rhythm Pharmaceuticals
RYTM
$6.75B
$5.98M 0.6%
201,046
-33,800
-14% -$859K
EQ icon
19
Equillium
EQ
$118M
$5.75M 0.58%
1,074,285
– –
TNGX icon
20
Tango Therapeutics
TNGX
$3.94B
$5.72M 0.58%
500,000
– –
PANA.U
21
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$5.1M 0.51%
400,000
– –
ALPN
22
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.03M 0.51%
399,190
-95,000
-19% -$932K
KRON
23
DELISTED
Kronos Bio
KRON
$4.97M 0.5%
+166,250
New +$5.22M
KALA icon
24
KALA BIO
KALA
$10.1M
$4.08M 0.41%
241
+60
+33% +$1.13M
ALBO
25
DELISTED
Albireo Pharma Inc
ALBO
$3.75M 0.38%
100,000
– –
1
2

Similar funds

MWA
Monograph Wealth Advisors Manhattan Beach, California $1.22B AUM 24.22% 1-Year Est. Return
SFP
Shepherd Financial Partners Winchester, Massachusetts $1.22B AUM 28.54% 1-Year Est. Return
OCM
Once Capital Management New York $1.22B AUM 87.6% 1-Year Est. Return
TCM
Tributary Capital Management Omaha, Nebraska $1.22B AUM 44.12% 1-Year Est. Return
TCM
Thames Capital Management Roseland, New Jersey $1.22B AUM 391.75% 1-Year Est. Return
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
SL
Salomon & Ludwin Richmond, Virginia $1.22B AUM 19.42% 1-Year Est. Return

Samsara BioCapital's Q4 2020 Portfolio in Review

As of Q4 2020, Samsara BioCapital held 46 positions worth $994M, up 177% from $359M the previous quarter. Its ten largest holdings account for 87% of the portfolio.

Samsara BioCapital's Q4 2020 filing shows 10 new, 4 increased, 16 reduced and 3 closed positions. Its largest new stake was Chinook Therapeutics, Inc. Common Stock: 3,168,388 shares worth $50.3M. The largest sale was CureVac, an estimated $21.1M.

By sector, the portfolio is most concentrated in Financials at 51% of assets, followed by Healthcare and Miscellaneous.

  • Samsara BioCapital's largest Q4 2020 buy was Chinook Therapeutics, Inc. Common Stock: 3,168,388 shares worth $50.3M.
  • Samsara BioCapital added most to Syros Pharmaceuticals, Inc. Common Stock in Q4 2020, an estimated $7.13M increase.
  • Samsara BioCapital's biggest Q4 2020 reduction was CureVac, cutting an estimated $21.1M.
  • Samsara BioCapital fully exited Aimmune Therapeutics in Q4 2020, selling an estimated $2M.
  • Samsara BioCapital's ten largest holdings make up 87% of its $994M portfolio in Q4 2020.
  • Samsara BioCapital opened 10 new positions and closed 3 in Q4 2020.
  • Samsara BioCapital's portfolio value rose 177% quarter-over-quarter to $994M.

Based on Samsara BioCapital's 13F filing for Q4 2020, filed 17 Feb 2021.